Several pharmaceutical and life science companies are moving beyond the standard protocols to build action-oriented environmental, social and governance (ESG) efforts across their business ranging from clinical trials to supply chains. ESG is a crucial driver for capturing opportunities and remaining ahead of vulnerabilities.

The integration of ESG strategy into clinical trials with regard to patient safety and privacy and in compliance with ethical and legal standards is bringing reform to the ways clinical trials are being conducted.

Discover the leading ESG clinical trials companies

Clinical Trials Arena has listed some of the leading companies offering products and services related to ESG using its intel, insights, and decades-long experience in the sector.

The information provided in the download document is drafted for clinical trial executives and technology leaders involved in ESG innovations.

The download contains detailed information on suppliers and their product offerings, as well as contact details to aid purchase or hiring decisions.

Amongst the leading suppliers of ESG in clinical trials are MedAble, IQVIA, Eli Lilly, Merck, Novartis, Johnson & Johnson, GlaxoSmithKline, Biogen, Pfizer, and Bristol-Meyers Squibb.

How ESG is improving operational excellence in clinical trials?

ESG can address some of the biggest health-related challenges worldwide including access to healthcare. It can simplify the patient journey and extend accessibility across more diverse patient populations while safeguarding scientific integrity, which is critical to overall drug development.

The ESG initiatives can maximise trial efficiency through protocol automation and improve social elements by making it easier for patients to join clinical trials, irrespective of their location, mobility, and economic issues. It can help in improving the carbon footprint of pharmaceutical companies by various methods such as reducing the need for patients to travel.

Ways to improve diversity in clinical trials

Some of the key strategies for enhancing diversity in clinical trials during research and development of novel medicines are generating clinical trial recruitment networks in underserved communities and establishing sustainable community-building efforts. These include investing in long-term health education while providing standardised platforms and engaging the community in conversations.